u3-1565
Advanced Solid Malignant Tumors
Daiichi SankyoPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Advanced Solid Malignant Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ds-6051b Daiichi Sankyo Co., Ltd. | Phase 1 | CC |
ds-1123 Daiichi Sankyo Co., Ltd. | Phase 1 | CC |
ds-5573a Daiichi Sankyo Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
u3-1565 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →